Loreen Fournier

FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.

J. Dahm-Daphi, L. Kachnic, H. Willers, 2011, Cancer letters.

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.

L. Kachnic, H. Willers, Li Li, 2010, Cancer letters.